dengue virus

Mice receiving the treatment produced their own monoclonal antibodies and survived infection with the life-threatening pathogen Pseudomonas aeruginosa.

A memory B cell response to Zika virus in dengue-infected patients produced antibodies that were poorly neutralizing in vitro and instead enhanced infection.

The mosquitoes that carry Zika may be able to transmit two other viruses at the same time.

The bacterium causes eggs to die, and spreading treated insects is expected to curb Aedes aegypti populations.

Researchers report evidence of antibody-dependent enhancement in a Zika-infected, immunocompromised mouse model.

Infected with Wolbachia, the insects are expected to reduce the spread of dengue and Zika. But scientists say the approach may have limitations.

Field data from the biotech company Oxitec show that releasing genetically modified male mosquitoes whose offspring die helped reduce dengue cases by 90 percent in one year.

Epidemic may be peaking and could end within three years, scientists suggest; dengue antibodies enhance risk of Zika infection; considering new strategies for the control of mosquito-borne disease outbreaks

Researchers examine the blood of people infected with dengue virus, finding a few Zika-neutralizing antibodies among mostly enhancing ones.

A selection of notable quotes from the American Society for Microbiology’s annual meeting

The viral infection causes symptoms similar to those associated with Zika and dengue viruses. 

Infecting mosquitoes with Wolbachia greatly reduces the insects’ abilities to transmit the virus.

Previous flavivirus infection could help explain the severity of symptoms in some people infected during the ongoing Zika outbreak, researchers report.

March 2016's selection of notable quotes

A Brazilian town will ramp up the release of insects engineered to shrink mosquito populations.

Mexico’s health ministry has OKed the vaccine for people between nine and 45 years old.

Researchers identify a novel virus in blood samples taken in the 1970s.

Researchers characterize a protein that could be key to the virus’s virulence—and to developing a vaccine against the mosquito-borne disease.

Immune cells specific for the virus are present in the skin of infected patients, a study shows.

Researchers uncover a class of antibodies that may confer immunity to different serotypes of the dengue virus.